On a recent call with analysts at BMO Capital Markets, an enigmatic “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—raised ...

director of the Center for Biologics Evaluation and Research (CBER), who resigned Friday. Marks’ effectiveness at the Food and Drug Administration saved countless lives and greatly advanced the ...

Dr. Peter Marks, who has served since 2016 as the director of the Center for Biologics Evaluation and Research (CBER) within the FDA, said in a letter to Acting FDA Commissioner Sara Benner that ...

Steele has been a full-time adviser to CBER since late 2022, according to his LinkedIn profile. Before that, he advised the FDA's Office of Medical Policy Initiatives from June 2020 to September 2022.

INDIANAPOLIS — A new study from Ball State University’s Center for Business and Economic Research (CBER) sheds light on how significant changes in Indiana's school funding policies have reshaped the ...